4.8 Review

Primary brain tumours in adults

Journal

LANCET
Volume 402, Issue 10412, Pages 1564-1579

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(23)01054-1

Keywords

-

Ask authors/readers for more resources

The most common adult-type primary CNS tumors are diffuse gliomas, but there are also various rare CNS tumor types. The classification of these tumors is increasingly based on molecular diagnostics. Surgery is the mainstay of treatment for gliomas, and early surgery is recommended for patients with histologically low-grade tumors. Standard treatment for adult-type diffuse glioma consists of radiotherapy and chemotherapy. Targeted treatments and immunotherapy are still in the early stages of development for the treatment of adult-type gliomas.
The most frequent adult-type primary CNS tumours are diffuse gliomas, but a large variety of rarer CNS tumour types exists. The classification of these tumours is increasingly based on molecular diagnostics, which is reflected in the extensive molecular foundation of the recent WHO 2021 classification of CNS tumours. Resection as extensive as is safely possible is the cornerstone of treatment in most gliomas, and is now also recommended early in the treatment of patients with radiological evidence of histologically low-grade tumours. For the adult-type diffuse glioma, standard of care is a combination of radiotherapy and chemotherapy. Although treatment with curative intent is not available, combined modality treatment has resulted in long-term survival (>10-20 years) for some patients with isocitrate dehydrogenase (IDH) mutant tumours. Other rarer tumours require tailored approaches, best delivered in specialised centres. Targeted treatments based on molecular alterations still only play a minor role in the treatment landscape of adult-type diffuse glioma, and today are mainly limited to patients with tumours with BRAFV600E (ie, Val600Glu) mutations. Immunotherapy for CNS tumours is still in its infancy, and so far, trials with checkpoint inhibitors and vaccination studies have not shown improvement in patient outcomes in glioblastoma. Current research is focused on improving our understanding of the immunosuppressive tumour environment, the molecular heterogeneity of tumours, and the role of tumour microtube network connections between cells in the tumour microenvironment. These factors all appear to play a role in treatment resistance, and indicate that novel approaches are needed to further improve outcomes of patients with CNS tumours.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available